Latest news

Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450

Debiopharm International SA Announces Clinical Collaboration with the Merck-Pfizer Alliance in Cancer Immunotherapy

Coorpacademy raises 10 million euros and achieves one of the most important fundraisings in the European EdTech sector

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2016 JCA-Mauvernay Award

Debiopharm invests double digit millions in the Canadian startup GenePOC, specialized in the development of rapid diagnostic tests

Debiopharm acquires a majority holding in the Canadian start-up GenePOC

Grand succès du Challenge Debiopharm Inartis

Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer

FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer